Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Sanchi-Tongshu Capsule (Enteric Coated) in Healthy Males
NCT02316730Phase 1Completed
- Sponsor
- Chengdu Huasun Technology Group Inc., Ltd.
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sanqi tongshu in ischemic stroke and cardiovascular diseases (CVD) (2 arms), sponsored by Chengdu Huasun Technology Group Inc., Ltd. Primary endpoints: Area under the plasma concentration-time curve from zero to 33 hours post dose, Area under the plasma concentration-time curve from zero to infinity post dose and 1 more. Started Jun 2014; status: completed.
02
Drugs
sanqi tongshu
03
Conditions
ischemic strokecardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT02316730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316730.